Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor

Mediators of Inflammation

Volumn 6, Issue 1, 1997, Pages 32-38

  Romano, M ^a   Faggioni, R ^a   Sironi, M ^a   Sacco, S ^a   Echtenacher, B ^b   Di Santo, E ^a   Salmona, M ^a   Ghezzi, P ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Air pouch; Inflammation; Tumour necrosis factor

Indexed keywords

CARRAGEENAN; DEXAMETHASONE; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; PROSTAGLANDIN E2; SERUM AMYLOID A; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; INFLAMMATION; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0031041039     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359791901     Document Type: Article

References (30)

1. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21: S447-S463.
2. Remick DG. Significance of in vivo detection of tumor necrosis factor. Lab Invest 1991; 65: 259-261.
3. Sekut L, Menius JA, Brackeen MF, Connolly KM. Evaluation of the significance of elevate levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J Lab Clin Med 1994; 124: 813-820.
4. Hopkins SJ, Meager A. Cytokines in synovial fluid: the presence of tumor necrosis factor and interferon. Clin Exp Immunol 1988; 73: 88-92.
5. Husby G, Williams RC. Synovial localization of TNF in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-371.
6. Oliver TS, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of tumor necrosis factor in the joints of adjuvant arthritic rats. Cytokine 1993; 5: 298-304.
7. Keffer J, Probert L, Caslaris H, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-4031.
8. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis and Rheumatism 1993; 36: 1681-1690.
9. Sedgwick AD, Sin YM, Edwards JCW, Willoughby DA. Increased inflammatory reactivity in newly formed lining tissue. J Pathol 1983; 141: 483-495.
10. Edward JCW, Sedgwick AD, Willoughby DA. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol 1981; 134: 147-156.
11. Kunkel SL, Chensue SW. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Comm 1985; 128: 892-897.
12. 2-induced suppression. J Immunol 1989; 142: 4346-4350.
13. 2 and cyclic nucleotides. J Immunol 1988; 141: 2388-2393.
14. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982; 389: 39-48.
15. Gadina M, Bertini R, Mengozzi M, Zandalasini M, Mantovani A, Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucorticoid-resistant models of endotoxic shock. J Exp Med 1991; 173: 1305-1310.
16. Catherine G, Bruyns C, Marchant A, et al. Interleukin-10 reduces the release of tumor necrosis factor and prevents the lethality in experimental endotoxemia. J Exp Med 1993; 177: 547-550.
17. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208.
18. Bentler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
19. Brennan FM, Chantry D, Jackson A, Maini R, Feldman M. Inhibitory effect of tumor necrosis factor-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 244-247.
20. Sipe JD, Gonnermann WA, Loose LD, Knapschoefer G, Xie WJ, Franzblon C. Direct binding enzyme linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods 1989; 125: 125-135.
21. Won K, Campos SP, Baumann H. Experimental systems for studying hepatic acute phase response. In: Mackiewicz A, Kushner I, Baumann H eds. Acute Phase Proteins. Boca Raton. FL: CRC Press, 1995; 255-271.
22. Braga da Motta JI, Cunha FQ, Vargaftig BB, Ferreira SH. Drug modulation of antigen-induced paw oedema in guinea pigs: effects of lipolysaccharide, tumor necrosis factor and leucocyte depletion. Br J Pharmacol 1994; 112: 111-116.
23. Fattori E, Cappelletti M, Costa P, et al. Defective inflammatory response in IL-6 deficient mice. J Exp Med 1994; 180: 1243-1250.
24. Sin YM, Sedgwick AD, Chea EP, Willoughby DA. Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann Rheum Dis 1986; 45: 873-877.
25. Zhang Y, Ramos HF, Jakschik BA. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 1992; 258: 1957-1959.
26. Sin YM, Tan CH, Chan SF. Changes in histamine and prostaglandins in acute inflammatory air pouch in mice. Agents Actions 1989; 28: 98-102.
27. Sedgwick AD, Lees P. Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents Actions 1986; 18: 429-438.
28. Simmons PM, Salmon JA, Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol 1983; 32: 1353-1359.
29. 2 in rat resident and thioglycollate-elicited macrophages. J Lipid Mediators Cell Signaling 1994; 10: 283-294.
30. Pettipher ER, Wimberly DJ. Cyclooxygenase inhibitors enhance tumor necrosis factor production and mortality in murine endotoxic shock. Cytokine 1994; 6: 500-503.